Cemile Gunalp, MD

Gastroenterologist Mouen Khashab specializes in therapeutic endoscopy, and he oversees this group of practitioners across the Johns Hopkins enterprise. Nationally and internationally known in the field of interventional endoscopy, Dr. Khashab has contributed immensely to the field’s advancement as a minimally invasive means to treat gastrointestinal and pancreaticobiliary disorders. Dr. Khashab earned his medical degree from the American University of Beirut Faculty of Medicine, and subsequently completed a residency in internal medicine and a fellowship in gastroenterology at Indiana University. He then completed a two-year fellowship at The Johns Hopkins Hospital before joining the faculty in 2011. A busy researcher, Dr. Khashab has published more than 600 papers in peer-reviewed journals. In 2013, he described the procedure called gastric peroral endoscopic myotomy (known as G-POEM) and was able to disseminate and teach it all over the world. Other procedures that he expanded include peroral endoscopic myotomy (POEM), peroral endoscopic myotomy with fundoplication (POEM-F), Zenker’s peroral endoscopic myotomy (Z-POEM) and full thickness resection. In 2022, he received the Master Endoscopist Award from the American Society for Gastrointestinal Endoscopy (ASGE) for his numerous contributions to the field. His procedural expertise includes endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS), interventional EUS, submucosal endoscopy, POEM/achalasia, endoscopic mucosal resection, endoscopic submucosal dissection, luminal stenting, large polyp resection and Barrett’s therapy, among others. Dr. Khashab is involved with multiple gastrointestinal societies and has served on many committees, including the ASGE Standards of Practice Committee, which is in charge of formulating guidelines for the practice of endoscopy. He has also served as an associate editor for the journal Endoscopy, a premier journal in the field. Khashab is a highly sought-after speaker at national and international conferences, and he has participated in multiple live endoscopy conferences. Outside of academic medicine, Dr. Khashab is an entrepreneur. His major interest is in new technology and medical devices, and his goal is to disrupt the field by introducing technology that makes endoscopic procedures safer, easier, efficient and more scalable.

Dr. Donald Small is the Kyle Haydock Professor of Oncology. He holds joint appointments in Pediatrics and Cellular and Molecular Medicine and Human Genetics. He also directs the Johns Hopkins/National Cancer Institute Pediatric Hematology/Oncology Fellowship program. Dr. Small received his undergraduate, and then M.D. and Ph.D. degrees from the Johns Hopkins University in 1979 and 1985. His Ph.D. research was conducted with Bert Vogelstein in the Oncology Department and his postdoctoral research with Tom Kelly in the Molecular Biology and Genetics Department. He trained in pediatrics and pediatric hematology/oncology at Johns Hopkins and joined the faculty in 1990. Dr. Small’s laboratory was the first to clone the human FLT3 gene that is the most frequently mutated gene in acute myeloid leukemia (AML) and results in very poor chances of cure for these patients. The investigations of FLT3 led Dr. Small and his team to discover drugs able to inhibit the cancer-generating activity of this important gene. His laboratory showed that a new class of drugs known as tyrosine kinase inhibitors could kill FLT3-affected cells, thus developing one of the earliest molecularly targeted cancer therapies. They then developed a test that enabled them to screen a host of additional kinase inhibitors and find several with great potency against FLT3. His group also led the first clinical trials investigating the use of a FLT3 inhibitor in adult relapsed and refractory FLT3 mutant AML, and determined how best to combine these drugs with chemotherapy. They also helped design the first pediatric trials of FLT3 inhibitors in pediatric AML and infant ALL. Dr. Small’s lab continues to investigate leukemic processes and the role of stem cells in governing the activities of the FLT3 gene in leukemia.